Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financi...(ted to those related to: our reliance on...)

Date:2/26/2008

ted to, those related to: our reliance on Masimo SET and related products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; the failure to continue developing innovative products and technologies; the introduction of competing products; the lack of acceptance of any new products and technologies, including the recently announced total hemoglobin measurement and including whether regulatory clearances will be obtained, the loss of our customers; increases in prices for raw materials or the loss of key supplier contracts; the failure to retain and recruit senior management and manage expected growth; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-Q for the quarter ended September 29, 2007, filed with the Securities and Exchange Commission on November 1, 2007. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the risk factors contained in our quarterly report on Form 10-Q for the quarter ended September 29, 2007, whether as a result of new information, future events or otherwise, exc
'/>"/>

SOURCE Masimo Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. Masimo Announces Continuous Noninvasive Total Hemoglobin
2. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
3. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
4. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
5. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
6. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
7. Masimo Reports Second Quarter 2007 Financial Results
8. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
9. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
10. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
11. Phlo Reports Sharp Revenue Increase